COVID-19 pandemic: A multidimensional analysis and the strategic role played by developing countries vaccine manufacturers

Abstract

Contribution of Developing Countries Vaccine Manufacturers (DCVMs) in the vaccine response to the COVID-19 pandemic crisis in 2021-2022 has been paramount, totaling 9.81 billion of the 15.91 billion vaccine doses distributed [1]. However, since many DCVMs acted as licensees or contract-manufacturing organizations (CMOs) of alternate developers, global understanding and knowledge of the magnitude of this contribution is understated. This paper aims at documenting and analyzing in further details the critical and central role played by DCVMs in the vaccine response to tackle the COVID-19 pandemic.

Keywords: COVID-19 vaccine; Capacity; Covid-19; DCVMN; Developing countries; Developing countries vaccine manufacturers; Emergency use authorization (EUA); Full market authorization (FMA); Investments; Pandemic; Public health emergency of international concern (PHEIC); Regulatory harmonization; SARS-CoV-2; Scale-up; Technology platforms; Vaccine; Vaccine development; Vaccine hesitancy; Vaccine manufacturers.